GlassScriptPhysician profile
Diana L Pollock
NPI 1609825942
$15,769.57
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $2,128 · 2020: $10K · 2021: $3,471 · 2022: $29.78.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $9,566.96 | 2019-2021 | |
| Biogen, INC. | $942.84 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $415.48 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $363.37 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $349.77 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $320.77 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $269.13 | 2019-2021 | |
| Amgen INC. | $263.89 | 2019-2021 | |
| Eisai INC. | $259.94 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $259.44 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $243.64 | 2020-2021 | |
| Abbvie INC. | $224.45 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $212.71 | 2019-2021 | |
| Sk Life Science, INC. | $203.91 | 2020-2021 | |
| Lundbeck LLC | $195.01 | 2019-2021 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $182.98 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $175.49 | 2019-2021 | |
| Ucb, INC. | $130.31 | 2019-2021 | |
| Harmony Biosciences LLC | $127.93 | 2020 | |
| Adamas Pharmaceuticals, INC. | $120.20 | 2019-2021 | |
| Bausch Health US, LLC | $112.07 | 2019 | |
| Greenwich Biosciences, INC. | $98.30 | 2020-2021 | |
| Zyla Life Sciences, INC. | $88.46 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $71.45 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $67.68 | 2020-2021 | |
| Almatica Pharma LLC | $66.50 | 2021 | |
| Neurocrine Biosciences, INC. | $65.58 | 2019 | |
| Supernus Pharmaceuticals, INC. | $59.90 | 2019-2021 | |
| Portola Pharmaceuticals, LLC | $57.55 | 2020 | |
| Grt US Holding, INC. | $37.13 | 2019-2020 | |
| Catalyst Pharmaceuticals, INC. | $33.70 | 2020 | |
| Csl Behring | $28.73 | 2019 | |
| Scilex Pharmaceuticals INC. | $26.99 | 2019 | |
| Promius Pharma LLC | $26.46 | 2019 | |
| Acorda Therapeutics, INC | $23.50 | 2019 | |
| Vanda Pharmaceuticals INC. | $21.89 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.94 | 2019 | |
| Merck Sharp & Dohme LLC | $14.12 | 2020 | |
| Ge Healthcare | $13.87 | 2019 | |
| Kyowa Kirin, INC. | $11.53 | 2019 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$2,500.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Pollock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.